Abstract:Background: Metabolism-associated fatty liver disease (MAFLD) is a widespread metabolic disease affecting 25% of the global adult population following Westernized lifestyles. Lifestyle modifications, specifically adherence to healthy dietary patterns, are pivotal in preventing and mitigating this disease. Consuming milk and dairy products is considered a cornerstone of a healthy dietary pattern, gathering significant attention due to compelling evidence from observational studies. These studies suggest that a higher intake of milk and certain dairy products is associated with a reduced risk of MAFLD. However, the relative health benefits of high- compared to lower-fat milk is a current topic of interest, with ongoing debates about their equivalency in promoting metabolic health. Aims & Hypothesis: In a MAFLD mouse model, we aim to determine the dependence of milk’s fat content on hepatic steatosis and lipid metabolic pathways by comparing whole- (WFM) to non-fat (NFM) milk supplementation in high-fat diet-fed mice (HFD). We hypothesize that both WFM and NFM will significantly improve HFD-induced hepatic lipid accumulation but via differential molecular mechanisms. Methods: Two cohorts of n=24 and n=36 6-week-old male C57BL/6 mice were acclimatized for one week, then randomly assigned to a HFD (45 kcal% fat) or a low-fat diet (LFD; 10 kcal% fat) control group. The HFD mice were randomized to either a WFM or NFM treatment of 0.425 mL milk for 8 weeks. At the end of the study, mice underwent an insulin tolerance and pyruvate tolerance test and body composition was measured. The animals were then euthanized, tissues were collected, and hepatic lipid metabolism was compared using western blot, histology, hepatic lipid assays, gas chromatography, and qPCR. Statistics were then completed using GraphPad Prism software 7.0, utilizing T-test, one-way ANOVA, and Tukey’s post-hoc tests with a p-value ≤ 0.05 considered as statistically significant. Results: Body weight gain was significantly reduced in NFM groups compared to HFD and WFM, accounted for by a significant reduction in fat mass. ITT was unaltered when corrected to baseline, but NFM groups had significantly higher PTT values when corrected to baseline. Overnight-fasted blood glucose was significantly reduced in NFM animals compared to WFM animals, suggesting an altered metabolic state between the two treatment groups. Histological results indicate a significant reduction in lipid accumulation by the NFM group compared to the HFD group (p<0.05), with WFM trending towards a similar reduction (p=0.051). Hepatic triglyceride concentrations were significantly reduced in NFM animals compared to WFM and HFD animals, suggesting a greater effect of NFM in reducing hepatic steatosis. Hepatic molecular results display an enhancement of enzymes involved in fatty acid oxidation and export pathways in the NFM group. In contrast, WFM displays an enhancement of de novo lipogenesis, fatty acid uptake, and fatty acid oxidation. Conclusion: The findings suggest that NFM may be more effective at reducing hepatic steatosis through enhanced fatty acid oxidation and export. WFM may reduce steatosis less effectively because of counteractive effects on fatty acid uptake and de novo lipogenesis versus beta-oxidation. These results provide mechanistic evidence of the protective effects of milk on MAFLD. The funding sources for this project include the Alberta Diabetes Institute Studentship Grant, CIHR Canadian Graduate Studentship, and Dairy Farmers of Canada. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Exploring the metabolic and molecular benefits of methyl donor supplementation in a model of metabolic and fatty liver disease

Effect of methyl donor supplementation on gut microbiota and hepatic expression of key miRNAs in a murine model of MAFLD

P- 25 METABOLIC, HISTOLOGICAL AND INFLAMMATORY BENEFITS IN A MURINE MODEL OF ALCOHOLIC STEATOHEPATITIS USING METHYL-GROUP DONOR SUPPLEMENTATION

O-21 NUTRITIONAL SUPPLEMENTATION WITH MEXICAN FOODS, OPUNTIA FICUS INDICA, THEOBROMA CACAO, AND ACHETA DOMESTICUS IMPROVED GUT-LIVER AXIS IN A MAFLD MICE MODEL.

Moringa oleifera Improves MAFLD by Inducing Epigenetic Modifications

[METTL3 inhibitor STM2457 improves metabolic dysfunction-associated fatty liver disease by regulating mitochondrial function in mice]

Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding

Mouse strain-dependent variation in metabolic associated fatty liver disease (MAFLD): a comprehensive resource tool for pre-clinical studies

Tandem Mass Tag-based Quantitative Proteomics Analysis of Metabolic Associated Fatty Liver Disease Induced by High Fat Diet in Mice.

MexMix supplementation prevented MAFLD development by restoring microbiota-gut-liver axis in a mice model.

Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model

Unravelling the role of mitochondrial dysfunction in the switching towards progressive MASLD by exploiting an AMLN diet-fed mouse model

Impacts of Non- and Whole-fat Milk Supplementation on Metabolism-Associated Fatty Liver Disease (MAFLD) in C57BL/6 Mice

Molecular pathogenesis of metabolic dysfunction‐associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Accompanied by Increased Activities of Superoxide Dismutase, Catalase, and Carbonyl Reductase 1 and Levels of miR-200b-3p in Mouse Models

Beneficial effects of MGL‐3196 and BAM15 combination in a mouse model of fatty liver disease

Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced metabolic-associated fatty liver disease via upregulation of Nrf2/HO-1 expressions in C57BL/6J mice

Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet

Efficacy and mechanism of intermittent fasting in metabolic associated fatty liver disease based on ultraperformance liquid chromatography-tandem mass spectrometry

Metabolic-Dysfunction Associated Liver Disease Progresses Independent of Weight in a Rodent Model

METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression